At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed pancreatic adenocarcinoma or poorly differentiated carcinoma originating in the pancreas
- ✓Locally advanced or metastatic disease
- ✓Not eligible for curative resection
- ✓Must have measurable or evaluable disease as defined by RECIST criteria (not CA19-9 elevation alone)
- ✕Known brain metastases
- ✕Prior gemcitabine
- ✕Prior imatinib mesylate
- ✕Inability to ingest tablets
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Imatinib Mesylate and Gemcitabine for First-line Treatment of Metastatic Pancreatic Cancer
In Brief
A Phase 2 clinical trial evaluating gemcitabine hydrochloride and imatinib mesylate for Pancreatic Cancer. Completed, enrolled 44 participants across 8 sites.
Detailed Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gemcitabine together with imatinib mesylate may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with imatinib mesylate works as first-line therapy in treating patients with locally advanced or metastatic pancreatic cancer.